The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LXEO | +32.06% | N/A | N/A | -7% |
| S&P | +13.09% | +85.73% | +13.17% | +58% |
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.53M | -4.1% |
| Market Cap | $358.57M | 20.0% |
| Market Cap / Employee | $4.98M | 0.0% |
| Employees | 72 | 24.1% |
| Net Income | -$20.28M | 31.2% |
| EBITDA | -$21.12M | 32.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.00M | -73.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.74M | -25.6% |
| Short Term Debt | $2.72M | 1.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -66.08% | 9.7% |
| Return On Invested Capital | -52.43% | -6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.84M | -66.8% |
| Operating Free Cash Flow | -$29.55M | -65.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.56 | 0.98 | 1.51 | 2.59 | 43.26% |
| Price to Tangible Book Value | 1.56 | 0.98 | 1.51 | 2.59 | 43.26% |
| Enterprise Value to EBITDA | -3.95 | -0.73 | -1.70 | -13.76 | 180.46% |
| Return on Equity | -85.4% | -80.7% | -75.3% | -80.7% | -24.73% |
| Total Debt | $9.92M | $9.40M | $8.91M | $8.46M | -18.71% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
